Plain-English translation of NCT05197270 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing 4D-150, a new gene therapy treatment that is injected directly into the eye to help treat wet age-related macular degeneration (a serious eye disease that causes vision loss in older adults). The medication is given as a one-time injection, and researchers want to see if it can help reduce the need for repeated anti-VEGF injections that patients currently receive to slow the disease. You would be eligible if you already take anti-VEGF injections and they have helped protect your vision.
Wet age-related macular degeneration requires frequent eye injections to stop vision loss, which is burdensome for patients and can be hard to maintain long-term. This trial is testing whether a single gene therapy injection could provide longer-lasting benefit and reduce how often patients need treatment.
You likely qualify if…
You likely don't qualify if…
You would receive one injection of the medication into your eye on the first day of the study. After that, you would return to the clinic monthly for 2 years for eye exams and imaging to check if the treatment is working and to watch for any side effects. If you complete that part, you would then enter a longer follow-up period where you would be checked at least yearly through 5 years after your injection to make sure the treatment remains safe.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
United States